Pfizer buys generic company Hospira on a 36 x PE FY15; 30x FY16 Further evidence that investors can win out of global shakeup in Big Pharma Pfizer has paid a full price of $US17bn for Hospira which equates to a PE multiple of 36x for FY15. Pfizer has acquired Hospira, a speciality pharma and biosimilar drug company, which produces biosimilars of biologic drugs that are off patent. Consolidation among the big […]
pharma stocks
Insync Funds Management is a global equity specialist based in Sydney. Key team members own equity in the business and co-invest in the Fund alongside other investors.